netFormulary North Central London NHS
Joint Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.05  Expand sub section  Other antineoplastic drugs
Aflibercept infusion (Zaltrap®)
(Oncology)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

Provider notes

  • NMUH:
    • Non-formulary
    • See MHRA Drug Safety Update
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA307 (not recommended): Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
   
Alectinib tabs
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic).
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA438 (not recommended): Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
   
Atezolizumab
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA 520
 
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
   
Avelumab
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
AAAAAAAA

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE/CDF criteria
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  TA517: Avelumab for treating metastatic Merkel cell carcinoma
   
Axitinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA333: Axitinib for advanced renal cell carcinoma
   
Binimetinib tabs
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Bosutinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Link  NICE TA576 (not recommended): Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)
   
Brigatinib tabs
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
   
Carboplatin + paclitaxel (CROSS)
(Oesophageal cancer)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Approved as neo-adjuvant treatment before surgery for adenocarcinoma of the oesophagus or the gastro-oesophageal junction (JFC November 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
    • As above
  • WH:
    • Non-formulary
 
   
Carfilzomib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA 457
 
Link  NICE TA457: Carfilzomib for previously treated multiple myeloma
   
Ceritinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines. 
    • See link below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Dabrafenib caps
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Link  NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
   
Docetaxel + oxaliplatin + disodium folinate + fluorouracil (FLOT)
(Oesophageal cancer)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Approved gastric or gastro-oesophageal junction adenocarcinoma (JFC November 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
    • As above
  • WH:
    • Non-formulary
 
   
Durvalumab
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE/CDF criteria
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
   
Encorafenib caps
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Eribulin
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Link  NICE TA515 (not recommended): Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
   
Folinic acid + fluorouracil + irinotecan (FOLFIRI)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Approved for:

  • 2nd / 3rd line treatment of inoperable gasto-oesophageal adenocarcinoma (May 2015)
  • 2nd line for high grade neuroendocrine tumour (March 2016)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
 
   
Folinic acid + fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Approved for 1st line treatment of unresectable metastatic colorectal cancer (May 2015)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
 
   
Folinic acid + fluorouracil + oxaliplatin + irinotecan (mFOLFIRINOX)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Approved adjuvant treatment of pancreatic cancer (JFC September 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
 
   
Ibrutinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotheray prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See links below
 
Link  NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA437 (not recommended): Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)
Link  NICE TA452 (not recommended): Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Idelalisib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

Idelalisib should not be initiated as a first line treatment in chronic lymphocytic leukaemia (CLL) patients with 17p deletion or TP53 mutation - see 'Direct Communication' below

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  Direct Healthcare Professional Communication: Gilead (REF: 1101-16-208)
Link  NICE TA328 (not recommended): Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)
Link  NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
Link  NICE TA469 (not recommended): Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)
   
Ixazomib
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
   
Lenvatinib caps (Kisplyx®)
(Renal cell carcinoma)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
AAAAAAAA

DO NOT CONFUSE Kisplyx® AND Lenvima® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance for renal cell carcinoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Lenvatinib caps (Lenvima®)
(Differentiated thyroid carcinoma, Hepatocellular carcinoma)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
AAAAAAAA

DO NOT CONFUSE Kisplyx® AND Lenvima® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance for thyroid cancer and hepatocellular carcinoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Link  NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
   
Lutetium (177Lu) oxodotreotide injection
View adult BNF View SPC online View childrens BNF
Formulary
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
   
Palbociclib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Panitumumab
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Check for MHRA Drug Safety Updates
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA240 (not recommended): Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)
Link  NICE TA242 (not recommended): Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Link  NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
Panobinostat
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed Oncology Consultants ONLY.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Pembrolizumab injection
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See links below
 
Link  NICE TA357: Pembrolizumab for melanoma after ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Link  NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
   
Ponatinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See link below
 
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Ribociclib
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • RFL
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
 
Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Ruxolitinib
(Myelofibrosis)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See link below
 
Link  NICE TA356 (not recommended): Ruxolitinib for treating polycythaemia vera (terminated appraisal)
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Talimogene laherparepvec (Imlygic®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
   
Tivozanib
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

 

  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)

 

 

 

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
   
Trametinib tabs
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    •  This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
   
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
Arsenic Trioxide
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • Prior funding approval required
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
   
08.01.05  Expand sub section  Bevacizumab
Bevacizumab
(Oncology)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
    • Discuss with cancer pharmacy team before prescribing
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA118 (not recommended): Bevacizumab for the treatment of metastatic colorectal cancer
Link  NICE TA148 (not recommended): Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)
Link  NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA212 (not recommended): Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Link  NICE TA214 (not recommended): Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Link  NICE TA242 (not recommended): Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Link  NICE TA263 (not recommended): Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Link  NICE TA284 (not recommended): Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285 (not recommended): Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Link  NICE TA353 (not recommended): Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
Link  NICE TA436 (not recommended): Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)
   
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
Bortezomib injection
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Haematology Team ONLY
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA129: Multiple myeloma - bortezomib
Link  NICE TA228: 1st line treatment of multiple myeloma
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Link  NICE TA453 (not recommended): Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)
Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
   
08.01.05  Expand sub section  Brentuximab vedotin
Brentuximab vedotin
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL elecctronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
 
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
   
08.01.05  Expand sub section  Cetuximab
Cetuximab
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety Updates
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA145: Head and neck cancer - cetuximab
Link  NICE TA242 (not recommended): Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA472: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
   
08.01.05  Expand sub section  Crisantaspase
Crisantaspase
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
Dacarbazine
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
   
Temozolomide
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal but the service is not provided at NMUH.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Restricted to neuroendocrine (NET) patients (with capecitabine) and metastatic melanoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
 
Link  NICE TA121: Glioma (newly diagnosed and high grade)
Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
   
08.01.05  Expand sub section  Erlotinib
Erlotinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when use in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Oncology team ONLY.
    • See links below
  • RFL:
    • AS per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA227 (not recommended): Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
08.01.05  Expand sub section  Hydroxycarbamide
Hydroxycarbamide
(Malignant disease)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
 
   
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
Ipilimumab
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
   
08.01.05  Expand sub section  Mitotane to top
Mitotane
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Approved for metastatic adrenocortical carcinoma (JFC February 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
Pentostatin
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
08.01.05  Expand sub section  Platinum compounds
Carboplatin
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
   
Cisplatin
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
   
Oxaliplatin
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • Restricted for treatment of pancreatic, colorectal, oesophago-gastric cancers and lymphoma only
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
   
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
Procarbazine
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
   
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA444 (not recommended): Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
   
Cabozantinib caps (Cometriq®)
(Thyroid carcinoma)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance for the treatment of medullary thyroid cancer
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
   
Cabozantinib tabs (Cabometyx®)
(Renal cell carcinoma, Hepatocellular carcinoma)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance for the treatment of renal cell carcinoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Crizotinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Check MHRA drug safety alerts
    • See London Cancer Guidelines for the Treatment of Lung Cancer
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additonally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
   
Dasatinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patient this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA241: CML where treatment with imatinib has failed
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Everolimus (Afinitor®)
(Oncology)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

DO NOT CONFUSE Afinitor®, Votubia® AND Certican® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
    • TA432, 449 and 498 do not apply at NMUH as services not offered.
    • See links below
  • RFL:
    • As per NICE guidance (see below)
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Everolimus (Votubia®)
(Angiomyolipoma)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

DO NOT CONFUSE Afinitor®, Votubia® AND Certican® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Approved for renal angiomyoplipomas who are at risk of complications but who do not require immediate surgery, and is reserved for patients with multiple AMLs in one or both kidneys and one or more lesions of >3cm in diameter. Restricted to renal consultants in renal genetics specialist clinic only (July 2013)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See indication above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
Gefitinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Oncology Team ONLY.
    • See links below
  • RFL:
    • Approved for non-small cell lung cancer in line with NICE
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to the treatment of NSCLC with EGFR mutation.
 
Link  NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA374 (not recommended): Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Imatinib tabs
(CML, GIST)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Gilvec for GIST only.

Generic for all other indications.

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Haematology Team ONLY.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
 
Link  NICE TA209 (not recommended): Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA425 (not recommended): Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA70: Imatinib for chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
   
Lapatinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • Special Funding Approval required - seek advice from Oncology Pharmacist
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA257 (lapatinib not recommended): Lapatinib or trastuzumab in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
   
Nilotinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Pazopanib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • Approved for metastatic renal cell carcinoma only in line with NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
 
Link  NICE TA215: Pazopanib in renal cell cancer
   
Regorafenib tab
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria


Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
    • No restriction stated
  • WH:
    • Non-formulary to WH
 
Link  NICE TA334 (not recommended): Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA514 (not recommended): Regorafenib for previously treated advanced hepatocellular carcinoma
Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
   
Sorafenib tabs
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Sunitinib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic) 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
 
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Vemurafenib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA drug safety updates
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA269: Vemurafenib for treating malignant melanoma
   
08.01.05  Expand sub section  Taxanes
Cabazitaxel
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
 
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Docetaxel
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL:
    • Restricted for treatment of breast, prostate and non-small cell lung cancers
    • Prior funding approval required for treatment of prostate cancer and adjuvant treatment of breast cancer
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Breast and lung cancer
 
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA109: Breast cancer (early) - docetaxel
   
Paclitaxel
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below 
  • RFL:
    • Restricted for treatment of breast cancer and Kaposi's sarcoma (2nd line)
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA108 (not recommended): Paclitaxel for the adjuvant treatment of early node-positive breast cancer
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
   
Paclitaxel - Albumin Bound Formulation (Abraxane®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Approved for:

  • Adjuvant or neoadjuvant therapy and metastatic disease breast cancer for those with hypersensitivity to taxanes. Hypersensitivity is defined as grade 3 hypersensitivity (August 2013).
  • See NICE TA for use of Abraxane for other cancers

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • Restricted to breast cancer patients
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
 
Link  NICE TA362 (not recommended): Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
Irinotecan Hydrochloride
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • To be prescribed by the Oncology team only.
    • See links below
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
   
Topotecan
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
AAAAAAAA

See NICE TA for eligibility criteria

Providernotes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • TA183 not applicable at NMUH as service is not offered.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Topotecan is available for the treatment of relapsed SCLC
 
Link  NICE TA183: Cervical cancer (recurrent) - topotecan
Link  NICE TA184: Lung cancer (small-cell) - topotecan
Link  NICE TA389 (not recommended): Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Venetoclax tabs
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See Link below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
   
08.01.05  Expand sub section  Trabectedin
Trabectedin
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA185: Soft tissue sarcoma - trabectedin
Link  NICE TA389 (not recommended): Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trastuzumab to top
Olaratumab
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
   
Pertuzumab injection
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidane
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See links below
 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
   
Trastuzumab
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
AAAAAAAA

IV or SC

See NICE TA for eligibility criteria

Use Ontruzant brand as first choice IV trastuzumab (JFC July 2018).

 

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • Approved for breast cancer and adenocarcinoma of the stomach in line with NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
    • See links below
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Trastuzumab is indicated for metastatic breast cancer as per Cancer Network Guidelines
 
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
   
Trastuzumab emtansine (Kadcyla®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
Cancer Drugs Fund
AAAAAAAA

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Oncology Team Only
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
 
Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
   
08.01.05  Expand sub section  Tretinoin
Tretinoin capsules
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
AAAAAAAA

Provider notes

  • NMUH:
    • To be prescribed by the Haematology Team ONLY in emergencies prior to the patient being transferred to UCLH. This is kept in the Emergency Drug Cupboard ONLY. This is a critical medicine and doses must not be delayed.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
08.01.05  Expand sub section  Vismodegib
Vismodegib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
Cancer Drugs Fund
AAAAAAAA

Provider notes

  • NMUH:
    • To be prescribed by the Oncology Team ONLY if CDF funded
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NICE TA489 (not recommended): Vismodegib for treating basal cell carcinoma
   
 ....
 Non Formulary Items
Abemaciclib tabs

View adult BNF View SPC online View childrens BNF
Non Formulary

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
 
Amsacrine

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
 
Axicabtagene ciloleucel infusion

View adult BNF View SPC online View childrens BNF
Non Formulary

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
 
Bexarotene

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Carboplatin + paclitaxel
(Squamous cell carcinoma of anus)

View adult BNF View SPC online View childrens BNF
Non Formulary

Approved as first-line treatment for advanced squamous cell carcinoma of anus  (JFC March 2019). 

Note: Carboplatin AUC5 day 1 of 28 day cycles + paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of 28 day cycles. 6 cycles (each cycle 28 days) 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Elotuzumab

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
Link  NICE TA434 (not recommended): Elotuzumab for previously treated multiple myeloma (terminated appraisal)
 
Inotuzumab ozogamicin injection

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
 
Irinotecan pegylated liposomal

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
Link  NICE TA440 (not recommended): Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
 
Midostaurin

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
 
Necitumumab

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
High Cost Medicine
Link  NICE TA411 (not recommended): Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
 
Niraparib caps

View adult BNF View SPC online View childrens BNF
Non Formulary

See NICE TA for eligibility criteria.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
 
Pablociclib  (Ibrance®)

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
 
Porfimer Sodium

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
 
Ramucirumab

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
High Cost Medicine
Link  NICE TA378 (not recommended): Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Link  NICE TA403 (not recommended): Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
 
Rociletinib

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
 
Sonidegib  (Odomzo®)

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
 
Temoporfin

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
 
Temsirolimus

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
High Cost Medicine
Cancer Drugs Fund
Link  NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA207 (not recommended): Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)
 
Tisagenlecleucel cells dispersion for infusion

View adult BNF View SPC online View childrens BNF
Non Formulary

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
 
Vandetanib tabs

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
High Cost Medicine
Cancer Drugs Fund

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA550 (not recommended): Vandetanib for treating medullary thyroid cancer
 
Vosaroxin  (Qinprezo)

View adult BNF View SPC online View childrens BNF
Non Formulary
GP - Red
High Cost Medicine
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

GP - 1st

Medicines suitable for first-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - 2nd

Medicines suitable for second-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.  

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

  

GP - Grey

Medicines on hospital formularies which have not been reviewed for suitability in primary care.  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary